RxDoctor Payments Data

Rommel Go, MD

Family Medicine · Boaz, ALNPI 1477548469

Payments from drug & device makers

$15,653in general payments, 2019–2025

Across 991 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Amgen$1K
  • Novo Nordisk$972
  • AstraZeneca$909
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,48899%
  • Education$1661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)199$2,302
GSK75$1,254
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC71$1,090
Amgen65$1,019
Novo Nordisk68$972
AstraZeneca41$909
Novartis28$582
Merck28$504
Pfizer47$492
Lilly USA, LLC25$467
Indivior Inc.28$433
Amarin Pharma, Inc.21$422
Xeris Pharmaceuticals, Inc.10$363
Sanofi-aventis U.S. LLC19$346
Exact Sciences21$308
Boehringer Ingelheim18$243
Mylan Specialty L.p.14$237
Scilex Pharmaceuticals Inc.19$236
Otsuka America Pharmaceutical, Inc.13$236
Abbott10$213
Sunovion Pharmaceuticals Inc.22$207
Bayer9$203
Antares Pharma, Inc.13$202
Johnson & Johnson10$170
Esperion Therapeutics, Inc.7$134
MDD US Operations, LLC6$133
Astellas Pharma US Inc3$131
Medtronic(2 entities)6$124
Biodelivery Sciences International, Inc.1$116
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$93
Ironwood Pharmaceuticals, Inc6$91
Eisai Inc.6$91
Neurocrine Biosciences, Inc.4$81
Vanda Pharmaceuticals Inc.1$81
Braeburn Inc.4$79
Idorsia Pharmaceuticals US Inc5$77
Jazz Pharmaceuticals Inc.4$77
Biohaven Pharmaceutical Holding Company Ltd.3$76
Daiichi Sankyo Inc.5$76
Orexo US, Inc.5$68
Collegium Pharmaceutical, Inc.4$66
Gilead4$62
Arbor Pharmaceuticals, Inc.4$53
Grifols USA, LLC3$51
Biohaven Pharmaceuticals, Inc.3$44
Corcept Therapeutics2$38
Ardelyx, Inc.2$38
E.r. Squibb & Sons, L.L.C.3$34
Takeda Pharmaceuticals U.S.A., Inc.2$33
Axsome Therapeutics, Inc.2$31
Dexcom, Inc.2$29
Kowa Pharmaceuticals America, Inc.2$26
Aytu Biopharma, Inc.1$24
Ultragenyx Pharmaceutical Inc.1$23
Qiagen, LLC1$19
Phathom Pharmaceuticals, Inc.1$18
Genentech USA, Inc.1$17
Averitas Pharma Inc.1$17
Vertex1$17
Tolmar, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,653 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$137,289
Medicare patients
369
Services billed
3,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide187$217,824
MounjaroTirzepatide146$149,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter208$135,083
FarxigaDapagliflozin Propanediol163$111,651
JardianceEmpagliflozin128$97,960
EliquisApixaban108$74,548
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl292$58,749
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,959$45,965
TrulicityDulaglutide41$44,607
RybelsusSemaglutide41$44,142
ZubsolvBuprenorphine Hcl/Naloxone Hcl47$31,003
XareltoRivaroxaban42$29,654
LinzessLinaclotide54$29,010
EntrestoSacubitril/Valsartan31$28,312
Repatha SureclickEvolocumab50$27,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$972$261,966228 claims
Lilly USA, LLCMounjaro, Trulicity$467$193,717187 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,254$172,986287 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$909$140,666224 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$243$115,651163 claims
PfizerEliquis, Lyrica$492$80,592120 claims
Indivior Inc.Sublocade, Suboxone$433$41,08136 claims
Orexo US, Inc.Zubsolv$68$31,00347 claims
Johnson & JohnsonXarelto$170$29,65442 claims
AbbVieLinzess$2,302$29,01054 claims
NovartisEntresto$582$28,31231 claims
Otsuka America Pharmaceutical, Inc.Rexulti$236$20,95111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →